As Mammography Screenings Drop, Advanced Breast Cancer Cases Increase in First Months of COVID-19
February 15th 2021The study, presented at the 2020 San Antonio Breast Cancer Symposium, also found that time to first treatment dropped during this period of the coronavirus disease 2019 (COVID-19) pandemic.
Read More
Dr Alexey Aleshin: Persistent ctDNA Is Highly Predictive of Disease Outcome
January 9th 2021Changes in circulating tumor DNA (ctDNA) are indicative of treatment response in early-stage breast cancer, pointed out Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Read More
An abstract from last month’s San Antonio Breast Cancer Symposium identifies factors linked with longer-term controlled substance use after treatment of breast cancer with mastectomy plus breast reconstruction in women receiving opioids, benzodiazepines, and other sedative/hypnotics.
Read More
Dr Alexey Aleshin: Chemotherapy Is Meant to Eliminate, Reduce Disease Burden
January 1st 2021Through neoadjuvant chemotherapy we can downstage tumors, assess drug efficacy, and better segregate women by prognosis status for adjuvant treatment, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Read More
We examine the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Read More
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Read More
This article describes treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Read More
Supplemental materials for the article describing treatment patterns, toxicities, and health care service utilization and costs of women with metastatic breast cancer (mBC) initiating treatment with intravenous (IV) paclitaxel or IV nab-paclitaxel.
Read More
Dr Alexey Aleshin: I-SPY 2 Findings Show How We Can Dynamically Monitor ctDNA
December 18th 2020Patient plasma samples from this study show residual circulating tumor DNA (ctDNA) correlates with a poor prognosis in women with early-stage breast cancer, explained Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Read More
Uptick in Early-Stage Breast Cancer Diagnoses Seen Among Minority Women Following ACA Implementation
December 14th 2020Compared with before the Affordable Care Act (ACA), study results show there was an increase in diagnoses of early-stage breast cancer among younger vs older minority women after the act.
Read More
Dr Alexey Aleshin Highlights the Diagnostic Benefits of ctDNA in Early-Stage Breast Cancer
December 12th 2020Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Read More
Obesity May Fuel 40% Gap in Black, White Breast Cancer Mortality
December 7th 2020Overall survival from early breast cancer has steadily been increasing; however, simultaneous increases in obesity and obesity-related comorbidities may have contributed to the survival disparity seen between these patient groups.
Read More
Dr Aditya Bardia Highlights Immuno-Oncology Developments for Patients With TNBC
November 25th 2020Tecentriq (atezolizumab) was approved in 2019 for PD-L1–positive triple-negative breast cancer (TNBC), said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Read More
Bilateral Mastectomy Possibly Linked to Poor Self-Image Among Young Breast Cancer Survivors
November 10th 2020A recent study of female breast cancer survivors shows that feelings toward body image were consistently worse among those who had a bilateral mastectomy vs breast-conserving surgery.
Read More
Study Results Point to Possible Survival Link Between Elderly Age, Chemotherapy
November 7th 2020Having node-positive, estrogen receptor–positive breast cancer indicated a greater likelihood of overall survival following chemotherapy, despite having several comorbidities, after adjustment for confounders.
Read More
Dr Aditya Bardia: Further Research Is Needed to Understand Resistance to Sacituzumab Govitecan
November 1st 2020Despite FDA accelerated approval in April, we still need to learn more about resistance to this antibody drug conjugate, said Aditya Bardia, MBBS, MPH, breast medical oncologist, Massachusetts General Hospital, Harvard Medical School.
Read More
Axillary Surgery Approach Impacts BCRL Risk in Breast Cancer Patients
October 28th 2020A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.
Read More